A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus
NCT ID: NCT04838405
Last Updated: 2025-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
129 participants
INTERVENTIONAL
2021-04-29
2024-08-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
NCT06628362
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
NCT05814107
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
NCT05110846
A Study of CT-388 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT06525935
A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes
NCT04855292
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CT-388
SC dose of CT-388
CT-388
Synthetic Peptide
Placebo
SC dose of placebo matching CT-388 dose
Placebo
Placebo
CT-388 Optional
SC dose of CT-388
CT-388
Synthetic Peptide
CT-388 MD
SC dose of CT-388
CT-388
Synthetic Peptide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT-388
Synthetic Peptide
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-65 years old, inclusive
* BMI 27.0-40.0, inclusive
* Stable body weight for 2 months
Exclusion Criteria
* Uncontrolled hypertension
* History of malignancy
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Carmot Australia First Pty Ltd
INDUSTRY
Carmot Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Carmot Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Carmot Clinical Research Unit 101
Perth, Western Australia, Australia
Carmot Clinical Research Unit 105
Monterrey, Nuevo León, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Carmot Therapeutics, Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT-388-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.